STXS Stereotaxis

Stereotaxis to Participate in 20th Annual Craig-Hallum Institutional Investor Conference

Stereotaxis to Participate in 20th Annual Craig-Hallum Institutional Investor Conference

ST. LOUIS, May 25, 2023 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will participate in Craig-Hallum’s 20th Annual Institutional Investor Conference.

Mr. Fischel will be available on Wednesday, May 31, 2023 for one-on-one meetings with conference attendees.

“We appreciate the invitation by Craig-Hallum and look forward to sharing Stereotaxis’ differentiated technology, clinical value, and growth strategy with investors,” says Mr. Fischel.

About Stereotaxis

(NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit 



Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
EN
25/05/2023

Underlying

STXSStereotaxis

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Stereotaxis

 PRESS RELEASE
Free
STXS STEREOTAXIS

Stereotaxis Announces FDA Clearance and Launch of Synchrony System

Stereotaxis Announces FDA Clearance and Launch of Synchrony System ST. LOUIS, April 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has received U.S. Food and Drug Administration 510(k) clearance for the Synchrony™ system. Synchrony is designed to digitize and modernize the interventional cath lab. Synchrony’s slim and stunning 55” 4K ultra-high-definition display consolidates the viewing and control of all disparate systems in the lab, offering an enhanced pr...

April 6, 2026 1 EN
 PRESS RELEASE
Free
STXS STEREOTAXIS

Stereotaxis Reports 2025 Full Year Financial Results

Stereotaxis Reports 2025 Full Year Financial Results ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2025. “The past year saw tremendous progress with significant regulatory approvals globally, advancement of a broad pipeline of innovations, and revenue growth of over 20%. I’m proud of what our team has accomplished and excited for the year ahead,” said David Fischel, Chairman and CEO. “Th...

March 9, 2026 1 EN
 PRESS RELEASE
Free
STXS STEREOTAXIS

Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Resu...

Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026 ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 fourth quarter and full year on Monday, March 9, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments. What:Stereotaxis fourth quarter and full ...

February 12, 2026 1 EN
 PRESS RELEASE
Free
STXS STEREOTAXIS

Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program

Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of a new robotic electrophysiology program at Klinikum Fürth in Fürth, Germany. Klinikum Fürth is the first hospital in Germany to establish a leading heart rhythm program that incorporates the Genesis Robotic Magnetic Navigation System, advanced robotic technology that establishes a new standard of care for patients with arrhy...

February 9, 2026 1 EN
 PRESS RELEASE
Free
STXS STEREOTAXIS

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter

Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S. Food and Drug Administration (FDA) approval for the MAGiC™ Magnetic Interventional Ablation Catheter. “FDA approval of MAGiC is a significant milestone for Stereotaxis and the community of physicians pioneering robotics in electrophysiology. It ensures the benefits of Robotic Magnetic Navigation can support patients with comple...

January 6, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch